! The first patients have been dosed in an open-label, Phase 1b clinical trial of study in lowrisk MDS4. The primary endpoint for this trial is safety with key secondary endpoints including preliminary efficacy Dual Inhibition of IRAK1 and IRAK4 Provides Stronger Suppression of Inflammatory Cytokines Compared to IRAK4-selective Inhibitor2 Proof-of-Mechanism First-In-Human study enrolled 82 adults to characterize the safety, PK, PD of R835 IL6 25 1R835 is an investigational compound not approved by the FDA. ...

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q3 2022 Earnings Conference Call November 3, 2022 4:30 AM ET Company Participants Dolly Vance - Senior Advisor, Legal & Corporate Affairs Raul Rodriguez - President and CEO Wolfgang Dummer - Executive Vice President and Chief Medical Officer Dave Santos - Executive Vice President and Chief Commercial Officer Dean Schorno - Executive Vice President and Chief Financial Officer Conference Call Participants Carly Kenselaar - Citi Kristen Kluska - Cantor Fitzgerald Eun Y ...

| --- | --- | --- | |------------------------------|-------|-------| | | | | | | | | | Q3 2022 Financial Results | | | | Presentation November 3,2022 | | | | | | | 1 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1955 ("PSLRA") relating to, among other things, the development and commercialization of olutasidenib; the timing of launch of olutasidenib; the progress of the RIPK1 inhibitor program in collabo ...

Table of Contents FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 0-29889 (Mark One) Rigel Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 94-3248524 ...

| --- | --- | --- | |----------------------------|-------|-------| | | | | | | | | | | | | | Q2 2022 Financial Results | | | | Presentation August 2,2022 | | | | | | | 1 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1955 ("PSLRA") relating to, among other things, Rigel's licensing agreement with Forma Therapeutics Holdings, Inc. ("Forma Therapeutics") and the success thereof; Rigel's ability to successfu ...

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q2 2022 Earnings Conference Call August 2, 2022 4:30 PM ET Company Participants Dolly Vance - Executive Vice President, Corporate Affairs and General Counsel Raul Rodriguez - President and Chief Executive Officer Dave Santos - Executive Vice President and Chief Commercial Officer Wolfgang Dummer - Executive Vice President and Chief Medical Officer Dean Schorno - Executive Vice President and Chief Financial Officer Jorge Cortes - Director, Georgia Cancer Center. Augu ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 0-29889 Rigel Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 94-3248524 (Sta ...

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q1 2022 Earnings Conference Call May 3, 2022 4:30 PM ET Company Participants Dolly Vance - EVP, Corporate Affairs and General Counsel Raul Rodriguez - President and Chief Executive Officer Wolfgang Dummer - EVP and Chief Medical Officer Dave Santos - EVP and Chief Commercial Officer Dean Schorno - EVP and Chief Financial Officer Caroline Piatek - Associate Professor of Clinical Medicine Conference Call Participants Eun Yang - Jefferies Gary Nachman - BMO Capital Mar ...

Q1 2022 Financial Results Presentation 1 May 3, 2022 Forward-Looking Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1955 ("PSLRA") relating to, among other things, the timing of reporting topline data from the FORWARD trial in patients with wAIHA; enrollment and reporting of data from the Company's Phase 3 clinical trial of fostamatinib in hospitalized COVID-19 patients; the commercial success of TAVALISSE in the U.S. and ...

FORM 10-Q (Mark One) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 (Exact name of registrant as specified in its charter) Delaware 94-3248524 (State or other jurisdiction of incorporation or (I.R.S. Employer Identification No.) organization) 1180 Veterans Blvd. South San Francisco, CA 94080 (Address of principal executive offices) (Zip Code) (650) 624-1100 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY P ...